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Abstract 
In mouse epidermal carcinogenesis, the latest stage of malignant progression 
involves the transition from squamous cell carcinoma to a highly aggressive type of 
tumor with spindle morphology. In this work, we have isolated a minor epithelial cell 
subpopulation (CarC-R) contained in the highly malignant spindle carcinoma cell line 
CarC. CarC-R exhibited a drastic reduction in tumorigenicity when compared with 
CarC, but CarC-R-induced tumors were mainly sarcomatoid, although they 
subsequently reverted to the epithelial phenotype when tumor explants were recultured 
in vitro. Several single cell clones with either stable epithelial or fibroblastic phenotypes 
were isolated from an explanted CarC-R tumor (CarC-RT). All these cell lines 
contained the same specific point mutation in H-Ras codon 61, but while CarC spindle 
cells had lost the normal H-Ras allele it was retained in CarC-R and CarC-RT-derived 
cell lines. Furthermore, CarC cells have inactivated p16INK4a and p19INK4a/ARF 
transcription, while CarC-R and CarC-RT clones expressed p19 mRNA and protein but 
not p16. Altogether, these results suggest that CarC-R represents a precursor stage to 
CarC in malignant progression. Spectral karyotyping analysis revealed that CarC-R was 
highly aneuploid and contained many chromosomal abnormalities. In contrast, CarC 
had a diploid or tetraploid modal chromosome number and contained a specific 
T(14;15) translocation in all of the analyzed metaphases. The T(14;15) translocation 
was present in only a minority (1.9%) of CarC-R cells, but it was widely spread in 
CarC-RT and its derived cell clones, regardless of their epithelial or fibroblastic 





 It is believed that cancer arises from the stepwise accumulation of 
protooncogene and tumor suppressor gene mutations, and the progressive alteration of 
gene expression. One of the best characterized model systems with respect to genetic 
changes that contribute to tumor initiation, tumor outgrowth and malignant progression 
is the mouse skin model of chemical carcinogenesis (Yuspa et al., 1994, Frame et al., 
1998). Numerous benign papillomas develop on the dorsal skin of mice initiated by 7, 
12-dimethylbenz(a)anthracene (DMBA) and promoted by 12-O-tetradecanoylphorbol-
13-acetate (TPA). A small number of papillomas progress to form squamous cell 
carcinomas (SCCs), and spindle cell carcinomas (SpCCs) evolve late in carcinogenesis 
(Klein-Szanto et al., 1989), associated with down-regulation of epithelial differentiation 
markers, such as E-cadherin and keratins, and the induction of mesenchymal 
components, such as vimentin (Navarro et al., 1991; Ruggeri et al., 1992; Diaz-Guerra 
et al. 1992, Stoler et al., 1993). This phenomenon, referred to as epithelial-
mesenchymal transformation (EMT), is considered a crucial event in late stage 
tumorigenesis leading to a highly aggressive and metastatic type of tumor, and has also 
been observed in human cancer (Akhurst and Balmain, 1999; Thiery, 2002; Gotzmann 
et al., 2004).  
In the mouse skin carcinogenesis model, a specific activating A-T mutation at 
codon 61 of the H-Ras gene is involved in initiation of carcinogenesis (Quintanilla et 
al., 1986), and amplification/overexpression of the mutant H-Ras gene or loss of the 
remaining wild-type H-Ras allele is associated with malignant progression (Quintanilla 
et al., 1986; Bremner and Balmain, 1990; Bianchi et al., 1990; Rodriguez-Puebla et al., 
1999). Specifically, in cases where both squamous and spindle cell components could 
be identified within the same tumor, both components had the same DMBA-specific H-
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Ras gene mutation, but the spindle cell component showed a higher mutant to normal 
gene ratio (Buchmann et al., 1991). This, together with the demonstration that  both 
epithelial and spindle cell types share the same point mutations in both alleles of p53, a 
gene whose inactivation occur in about 40% of SCCs, but not in premalignant 
papillomas (Burns et al., 1991), provided a conclusive proof that SpCCs derive from 
pre-existing SCCs. In addition, it was found that loss or missregulation of the INK4 
locus encoding the cell cycle regulators p15INK4B, p16INK4A and p19INK4A/ARF 
correlated with the SCC-SpCC transition (Linardopoulos et al., 1995). These genetic 
alterations might drive the spindle transformation in cooperation with other epigenetic 
events, such as those triggered by transforming growth factor- (TGF-) signalling 
pathways (Akhurst and Balmain, 1999).  
Aneuploidy –that is, an imbalance in the normal diploid complement of 
chromosomes- and chromosomal aberrations are hallmarks of experimental and human 
cancer. They occur early in tumor formation and increase with tumor progression, 
suggesting they can play a role in both tumor development and malignancy (Pihan and 
Doxsey, 1999; Rajagopalan et al., 2003; Grady, 2004). In mouse skin carcinogenesis, 
aneuploidy and chromosomal abnormalities segregate with progressive dysplasia during 
malignant conversion from papillomas to SCCs (Conti et al., 1986; Aldaz et al., 1987), 
and trisomies of chromosome 7 (where the H-Ras gene locus is located) and 
chromosome 6 have been found in aneuploid papillomas (Aldaz et al., 1989). 
In this article, we have identified a precursor cell subpopulation (CarC-R) within 
a highly aggressive spindle carcinoma cell line (CarC). CarC-R cells are epithelial in 
culture and weakly tumorigenic in nude mice, but produce highly undifferentiated 
carcinomas in vivo. CarC-R cells are aneuploid and exhibit a high degree of 
chromosomal instability. In contrast, CarC cells have a diploid or tetraploid modal 
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number of chromosomes and are genetically more stable than CarC-R. A specific 
reciprocal chromosomal translocation T(14;15), which is associated with malignant 
progression, was characterized in CarC-R and CarC cells by spectral karyotyping 




The spindle carcinoma cell line CarC contains epithelial cells that exhibit 
phenotypic plasticity in vivo 
 The CarC cell line was developed from a poorly differentiated mouse skin 
carcinoma induced by initiation with DMBA and promotion with TPA (Bremner and 
Balmain, 1990). CarC cells are spindle-shaped in culture, and produce highly anaplastic 
spindle carcinomas upon injection in nude mice (Diaz-Guerra et al., 1992, Buchmann et 
al., 1991). Although CarC cell cultures have maintained a fibroblast-like appearance for 
more than 10 years (Figure 1), occasionally we observed the presence of isolated cells 
with an epithelial morphology in routine experiments in which CarC cells were passed 
at a high dilution. Thus, we isolated an epithelial cell subpopulation (CarC-R) from a 
late passage (p. > 50) CarC cell culture seeded at low density (Figure 1). CarC-R cells 
were grown, frozen, and studied as a separate cell line. Characterization of protein 
differentiation markers revealed that CarC-R cells synthesize E-cadherin and keratins, 
while the expression of these epithelial protein markers was not detected in CarC cell 
lysates (Supplementary Figure 1). Furthermore, E-cadherin in CarC-R cells was 
correctly located at cell-cell junctions, suggesting that it is actively mediating cell-cell 
interactions. CarC-R cells have been found to maintain a stable epithelial phenotype for 
at least 40 passages. 
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The tumorigenic properties of CarC and CarC-R cells were compared after 
transplantation in nude mice. CarC cells gave rise to highly aggressive spindle tumors 
(Figure 2a, c) at all injection sites (6 out of 6) with short latencies (8-14 days). In 
contrast, CarC-R cells produced tumors in only 33% of injection sites (2 out of 6) after 
long latency periods (35-56 days). Histological examination of CarC-R tumors revealed 
that they were highly undifferentiated, with large areas exhibiting an apparent spindle 
morphology and small regions (< 5%) containing epithelial cells with no squamous 
component (Figure 2b, d). The fact that CarC-R cells switched from an epithelial 
phenotype in vitro to a mesenchymal phenotype when placed into a subcutaneous 
environment in vivo suggested that they were phenotipically plastic, able to undergo a 
reversible EMT in vitro and in vivo (Portella et al., 1998). Indeed, when a cell line 
(CarC-RT) was derived from an explanted CarC-R tumor, it exhibited a mixed 
morphology containing cells of both epithelial and fibroblastic appearances, that tended 
to present a predominant epithelial morphology when the culture was propagated. As 
expected, CarC-RT cells exhibited higher tumorigenic properties than CarC-R, inducing 
tumors at all injection sites (4 out of 4) with latency periods close to that of CarC (16-29 
days). Nevertheless, tumors induced by CarC-RT cells were not completely spindle, but 
presented similar phenotypes as those of CarC-R (data not shown). Several single-cell 
clones that exhibited stable (at least for 20 passages) epithelial (E1, E4, E2) and 
fibroblastic (F2, F3, F4, F5) phenotypes were isolated from an early-passage CarC-RT 
cell culture (Figure 1, see also Supplementary Figure 1).  
 
Characterization of H-Ras, p53 and INK4a genetic alterations 
 The CarC cell line was reported to contain a characteristic DMBA-associated A-
T mutation in the codon 61 of the H-Ras gene and to have lost the normal H-Ras allele 
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(Bremner and Balmain, 1990; Buchmann et al., 1991). The H-Ras codon 61 mutation 
gives rise to a restriction site for XbaI enabling an easy verification of the mutation by 
the presence of two novel restriction fragments after digestion of the DNA with the 
enzyme (Quintanilla et al., 1986). We analyzed the status of H-Ras in CarC and the 
other cell lines by RT-PCR, using primers that amplify a 400-bp sequence containing 
the codon 61. The amplified cDNA fragments were fractionated in a gel before and after 
digestion with XbaI. The PDV squamous carcinoma cell line containing an identical 
codon 61 mutation at H-Ras as CarC, but retaining the normal H-Ras allele (Quintanilla 
et al., 1991), was used as a control. All of the cell lines exhibited the same XbaI 
polymorphism, but CarC-R and CarC-RT-derived cell clones expressed increased 
normal to mutant ratios of H-Ras when compared with CarC (Figure 3a). In this latter 
cell line, although most of the amplified cDNA was digested by the enzyme, a faint 
band migrating to the normal position was observed after a careful inspection of the gel. 
This DNA was amplified by PCR and identified as normal H-Ras by sequencing (data 
not shown). These results suggest that CarC-R represents a small subpopulation of CarC 
cells that retain the normal H-Ras allele. All of the CarC-RT-derived clones expressed 
normal and mutated H-Ras transcripts irrespective of their phenotype, although the ratio 
of normal to mutated expression tended to be lower in the fibroblastic clones, 
particularly in the clone F2.  
CarC cells have also been reported to have deleted the genes encoding the 
cyclin-dependent kinase inhibitors p15INK4b and p16INK4a, an event associated with 
the late spindle stage of tumor progression in skin carcinogenesis (Linardopoulos et al., 
1995). The locus INK4a is also transcribed into a second alternate mRNA, which 
originates from an independent first exon, encoding p19ARF (Quelle et al., 1995). To 
analyze the status of the INK4a locus in the cell lines, we studied the expression of p16 
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and p19 by RT-PCR and Western blotting. None of the cell lines expressed p16 mRNA 
(Figure 3b) or protein (Figure 3c). However, while no expression of p19 could be 
detected in CarC, significant levels of p19 transcripts and protein were found in CarC-R 
and CarC-RT-derived cell lines (Figure 3b, c). These results suggest that spindle CarC 
cells have inactivated the entire INK4a locus while CarC-R and its derived cell lines 
might contain INK4a alterations that inactivate p16, but not p19 gene expression. Since 
silencing of the p16 INK4a promoter by methylation has been found in a significant 
fraction of human tumors (Ruas and Peters, 1998; Serrano, 2000), we tested the effect 
of the methyltransferase inhibitor 5-aza-2’-deoxycytidine (5-aza-dC) on p16 expression. 
Western blot analysis showed that p16 protein was markedly up-regulated in CarC-R, 
but not in CarC cells, after a 48 h treatment with the drug (Figure 3d), indicating that 
inactivation of p16 gene transcription in CarC-R cells occurs by aberrant methylation of 
the promoter.  
We also studied the status of the p53 gene in the cell lines. To this aim, exons 3-
9 of the p53 sequence were amplified by RT-PCR and the resulting fragments purified 
and directly sequenced. This region contains the highly conserved DNA-binding core, 
where almost all mutations found in tumors occur (Vousden and Lu, 2002). No change 
could be detected in CarC, CarC-R and CarC-RT-derived cell clones respect to the 
normal sequence (Table 1), while an ATG to GTG point mutation at codon 234 was 
found in PDV carcinoma cells, as previously described (Burns et al., 1991). 
Finally, in order to rule out the possibility that CarC-R represented some 
contaminating cells in the CarC cell line, we performed a microsatellite marker 
polymorphism analysis. Three chromosome 1 (D1Mit294, D1Mit383, D1Mit15) and 
two chromosome 12 (D12Mit199 and D12Mit180) microsatellite markers were 
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amplified by PCR using specific markers. As shown in Supplementary Figure 2, all 
CarC, CarC-R, F2 and E2 cell lines showed the same pattern of allelic bands.  
 
Characterization of chromosomal abnormalities by spectral karyotyping 
 Karyotypic analysis of the cell lines revealed that CarC had a diploid or 
tetraploid modal chromosome number (Figure 4) and most of the aneuploid cells with 
non-modal chromosome numbers were near-diploid (40-50), near-tetraploid (71-90) or 
near-octaploid (close to 160). In contrast, CarC-R and CarC-RT-derived cell clones 
were highly aneuploid. CarC-R, with a mode of 66 chromosomes, was highly 
homogeneous with regard to the karyotype of individual cells, since about 72% of the 
cells had 61-70 chromosomes (Figure 4). Clones derived from CarC-RT were more 
heterogeneous than CarC-R and had modal chromosome numbers ranging from 84 to 
102 (data not shown).  
In order to study whether specific chromosomal aberrations correlated with the 
phenotype or tumorigenic characteristics of the cell lines, we carried out a SKY analysis 
in CarC, CarC-R and two clones of each phenotype, either epithelial or fibroblastic 
(Table 2). All metaphases analyzed in CarC showed the same T(14;15) reciprocal 
translocation (Figure 5a, b), and about 25% of the cells had in addition a T(11;19) 
translocation. The T(14;15) translocation was found to segregate with tumors induced 
by CarC in nude mice (data not shown).  While these were the only significant 
chromosomal aberrations found in CarC cells, CarC-R and CarC-RT-derived clones 
exhibited a wide variety of chromosomal abnormalities with the presence of 
Robertsonian translocations, deletions, insertions, amplifications, and gains and losses 
of chromosomes (Table 2 and Figure 5c). No specific alteration associated with either 
the epithelial or the fibroblastic phenotype was observed in the cell clones. 
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Interestingly, we were unable to detect the T(14;15) translocation in CarC-R cells with 
this method, even though we increased the number of analyzed metaphases up to 63. 
However, T(14;15) was recurrent in all of the studied CarC-RT-derived cell clones 
(Table 2). Since CarC-RT cells come from a tumor produced by CarC-R in a nude 
mouse after a long latency period, these results suggested that T(14;15) should be 
present in a small subpopulation of CarC-R cells that was selected in vivo during tumor 
formation. 
 
t(14;15) segregates with tumorigenicity  
 To confirm the above hypothesis, we carried out a FISH approach to analyze 
specifically the T(14;15) translocation in a higher number of CarC-R metaphases. Dual 
color FISH combining bacterial artificial chromosome (BAC) probes mapping at 
regions C, D1, D3 and E3 of chromosome 15 (Figure 6a) was then performed in CarC-
R, CarC-RT and CarC cells. As expected, most of CarC-RT and CarC metaphases 
contained a translocated chromosome 15 (Table 3), while it was present in only a small 
proportion of CarC-R cells (Table 3 and Figure. 6b). In all cases, the breakpoint in 
chromosome 15 was between regions D1 and D3, again indicating a common origin for 
all of these cell lines. To confirm that a portion of chromosome 15 was swapped with 
chromosome 14, we chose a BAC probe mapping at region A3 close to the chromosome 
14 centromere, together with BACs C and E3 of chromosome 15 (Figure 6c). The A3 
probe gave a diffuse spot (green) after hybridization, enabling distinction between this 
region in chromosome 14 and region C from chromosome 15. The finding of a 
translocated product containing the A3 fragment of chromosome 14 fused to the E3 
region derived from chromosome 15 as well as a product derived from chromosome 15 
that had lost the E3 region in the same metaphase (Figure 6c, d) unequivocally 
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demonstrated the presence of a reciprocal T(14;15) translocation in CarC-R, as found 
previously in CarC and CarC-RT-derived cell clones by SKY. The dual color metaphase 
FISH also revealed that T(14;15) was absent from premalignant MCA3D keratinocytes 
(data not shown), which are nontumorigenic upon injection in nude mice (Quintanilla et 
al., 1991), and served as a negative control. A summary of the detection of T(14;15) by 
FISH in CarC-R, CarC-RT and CarC cells is presented in Table 3. Overall, the data of 
Tables 2 and 3 indicated that only 1.9% of CarC-R cells contained the T(14;15) 
translocation (5 out of 263 metaphases), while it was widely distributed in CarC-RT and 
CarC cell populations with more than 90% of metaphases displaying T(14;15). The 
above results indicate that T(14;15) translocation segregates with tumorigenicity, since 
it was present in only a minority of CarC-R cells that were selected in vivo in the mouse 
to produce a tumor.  
 
Discussion 
 In this report, we have characterized a cell subpopulation (CarC-R) contained in 
a spindle carcinoma cell line (CarC) derived from a chemically-induced mouse skin 
tumor. CarC-R cells are epithelial in vitro and exhibit a drastic reduction in their 
tumorigenic properties when compared with CarC, yet they are phenotypically plastic in 
vivo, producing sarcomatoid carcinomas with only small (< 5%) epithelial cell 
components. Similarly, cell lines with an unstable phenotype, capable of eliciting a 
reversible EMT in vitro and in vivo, have been previously obtained by others, generally 
derived from primary tumors containing mixed spindle and epithelial cell components 
(Buchmann et al., 1991; Portella et al., 1998).  
Both CarC-R and CarC cell lines contain the same DMBA-specific A-T 
mutation at codon 61 of the H-Ras gene, which is associated with initiation of 
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carcinogenesis (Quintanilla et al., 1986). However, while CarC-R cells retain the normal 
H-Ras allele, it is lost in CarC spindle cells. Increased mutant to normal H-Ras ratios (or 
loss of the normal H-Ras allele) is a frequent characteristic associated with the SCC-
SpCC transition in vivo (Buchmann et al., 1991). Thus, fibroblastic cell clones derived 
from an explanted CarC-R tumor (CarC-RT) tended to express increased mutant to 
normal H-Ras transcript levels in comparison with epithelial cell clones derived from 
the same tumor. In particular, reduced expression of normal H-Ras was more evident in 
F2 cells. H-Ras is considered a major driving force for tumor progression in mouse skin 
carcinogenesis. The mutant H-Ras allele is frequently duplicated in papillomas and 
amplified to multiple copies or overexpressed in SCCs (Bremner and Balmain, 1990; 
Bianchi et al., 1990; Rodriguez-Puebla et al., 1999). Thus, successive increases in Ras 
activity appear to correlate with malignant potential, but this model requires down-
regulation or loss of downstream signals that would lead to growth arrest or cell death 
by enhanced Ras oncogenic activity, such as p16INK4a and p19INK4a/ARF (Frame 
and Balmain, 2000). In fact, deletions in the INK4 locus are frequent events associated 
with the late spindle stage of tumor progression, and CarC cells were found to have 
deleted the p15INK4b and p16INK4a genes (Linardopoulos et al., 1995). The INK4a 
locus encodes two transcripts, p16 and p19, originating from an alternate first exon and 
common second and third exons (Duro et al., 1995; Mao et al., 1995; Stone et al., 
1995). The finding that CarC spindle cells do not express p16 and p19 genes indicates 
that they have deleted the entire INK4a locus. In contrast, CarC-R cells express p19 
mRNA and protein, but they have silenced p16 transcriptional activity, likely by 
promoter methylation. These results suggest that sequential inactivation of p16 and p19 
occurs at later stages of tumor progression, the latter associated with the acquisition of a 
full malignant phenotype. This important role of p19 in malignancy is confirmed by 
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genetically engineered mouse models, where the inactivation of p19, but not p16, 
predispose to the development of spontaneous tumors (reviewed in Serrano, 2000; 
Sherr, 2001). In particular, regarding the susceptibility of these mice to DMBA-induced 
carcinogenesis, p16-deficient mice showed a similar frequency of skin tumors than 
wild-type mice (Sharpless et al., 2001), while in p19-deficient mice the number and 
growth rate of papillomas was increased, and progression to highly aggressive spindle 
cell carcinomas was accelerated (Kelly-Spratt et al., 2004).  
In addition to the above genetic alterations, we have identified in this work a 
reciprocal T(14;15) translocation, which is widely distributed in the CarC cell 
population, but present in only a minority (1.9 %) of CarC-R cells. T(14;15) is selected 
in vivo in tumors induced by CarC-R in nude mice, indicating that it is associated with 
malignancy. The fact that T(14;15) segregates with both epithelial and fibroblast clonal 
derivatives of CarC-RT indicates that it is not related to a particular phenotype. 
Although a T(14;15) was observed in a spontaneous thymic lymphoma developed in a 
mouse deficient for both histone H2AX and p53 (Celeste et al., 2003), to our knowledge 
T(14;15) translocations have not been found before in mouse epithelial tumors. The 
chromosome 15 breakpoint was mapped between clones RP23-236P20 (region D1) and 
RP23-6B22 (region D3), still separated by a long distance of approximately 17 Mb.  
Further studies are in progress to delineate the precise location of breakpoints in 
chromosomes 15 and 14, and to determine whether rearrangements of specific genes are 
involved in the translocation. In this respect, we have not observed significant changes 
in the expression of c-myc in the cell lines that could be related to this translocation 
(data not shown). c-myc is located in band D2 of chromosome 15, the region where 
T(14;15) appears to occur, and is involved in recurrent T(15;12) translocations 
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associated with pro-B cell lymphomas (Celeste et al., 2003; Difilippantonio et al., 
2002). 
The finding that CarC and CarC-R cell lines carry the same mutation at the H-
Ras gene, together with the presence of the same T(14;15) translocation and absence of 
mutations in the central core of the p53 gene argues in favour of a common origin, 
likely clonal for both cell lines. Furthermore, CarC-R appears to represent a stage 
previous to CarC in malignant progression, as suggested by their respective tumorigenic 
and phenotypic characteristics and the presence in CarC of additional genetic 
alterations; i.e., loss of the normal H-Ras allele, deletion of the INK4a/ARF locus and 
spread of T(14;15).  Nevertheless, the relationship between these two cell lines is not 
clear at present. CarC-R cells with a near-triploid (61-70) number of chromosomes are 
aneuploid and exhibit a wide variety of chromosomal aberrations. In contrast, most of 
CarC cells are near-diploid or near-tetraploid and are characterized by a single specific 
T(14;15) chromosomal translocation (and by a secondary T(11;19) translocation which 
is present in only about 25% of the cells). These results support previous reports 
showing an intimate relationship between chromosomal instability and the degree of 
aneuploidy (Lengauer et al., 1997; Lengauer et al., 1998; Miyoshi et al., 2000; Beheshti 
et al., 2001; Takahashi et al., 1999). Both events appear to occur early in tumorigenesis 
and precede malignant transformation (Duesberg et al., 1998; Duesberg et al., 1999; 
Shih et al., 2001). CarC cells could derive from the small CarC-R cell subpopulation 
that contains the T(14;15) translocation. Since no cell with T(14;15) could be found in 
CarC-R by SKY, it was not possible to determine whether these minority CarC-R cell 
subpopulation was aneuploid, like the vast majority of CarC-R cells, or near-
diploid/tetraploid as CarC. However, in vivo selection of CarC-R cells containing 
T(14;15) appears to indicate that these cells are in fact aneuploid, as seen by the 
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karyotypes displayed by CarC-RT-derived cell clones. Therefore, the prospect that CarC 
cells have evolved from a highly aneuploid, genetically unstable CarC-R cell 
subpopulation would imply that, at least in some cases, the degree of aneuploidy 
declines during the latest stages of tumor progression. It is thought that karyotypic 
instability would accelerate the rate of mutation in dividing cancer cells, generating in a 
stochastic manner new abnormal and heterogeneous karyotypes, most of which would 
be lethal. Cells containing a more balanced number of chromosomes and fixed genetic 
alterations conferring a growth advantage; i.e., increased mutant to normal H-Ras gene 
dosage, p16INK4a and p19ARF gene inactivation, and T(14;15), might have been 
selected for tumor progression with each wave of clonal expansion. Further studies 
within this cell model will test the feasibility of this hypothesis. 
 
Materials and Methods 
 
Cell lines, culture conditions and drug treatment 
To obtain the CarC-R cell line, CarC cells (p. > 50) were seeded at low density 
in 100 mm plastic dishes, and a colony of cells displaying an epithelial morphology 
(CarC-R) was isolated by a cloning ring. CarC-R cells were grown, expanded to several 
flasks, and frozen. The CarC-RT cell line was isolated from an explanted tumor induced 
by s.c. injection of CarC-R cells into the back of a nude mouse. Clones F2, F3, F4, F5, 
E1, E2, E4 were isolated from an early passage (p. 2) CarC-RT cell culture by cloning 
rings. Other cell lines used in this work were premalignant MCA3D and transformed 
PDV mouse keratinocytes (Kulesz-Martin et al., 1983, Fusenig et al., 1978). 
Cells were grown in Ham's F-12 medium supplemented with amino acids and 
vitamins (MCA3D, PDV) or Dulbecco's modified Eagle's medium (CarC, CarC-R, 
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CarC-RT cells and CarC-RT-derived clones), in the presence of 10% fetal calf serum 
(Gibco Invitrogen Corp., Barcelona, Spain) and antibiotics (100 µg/ml ampicillin, 32 
µg/ml gentamicin; 25 µg/ml amphotericin B; Sigma-Aldrich, Madrid, Spain). Cultures 
were maintained at 37 °C in a 5% CO2 humidified
 atmosphere. 
The methyltransferase inhibitor 5-aza-dC (Sigma-Aldrich) was used to test the 
effect of demethylation on p16 gene expression. Cells were treated with either 10 M 5-
aza-dC or the same volume of ethanol (used as a solvent for the drug) for 48 h. After 
treatment, cells were washed in PBS and harvested for Western blot analysis.    
 
RT-PCR analysis 
  RNA samples (2 g) isolated from the cell lines by the guanidinium thiocyanate 
procedure were incubated with the Moloney murine leukemia virus reverse transcriptase 
(Promega Corp., Madison, WI, USA), and the generated cDNAs were used for PCR 
amplification. For specific detection of mouse p16 and p19 mRNAs, we used 
oligonucleotides to amplify fragments corresponding to exon 1 (133-bp) and exon 1 
(205-bp) of the INK4a locus, as well as primers to amplify the entire coding region of 
p16 (516-bp) and p19 (586-bp). For mouse H-Ras, oligonucleotides to amplify a cDNA 
fragment containing the codon 61 were used. The 400-bp product was isolated using a 
gel extraction kit (QIAquick; QuiagenGmbH, Hilden, Germany). The presence of a 
DMBA-specific A-T mutation at codon 61 was verified by digestion of the DNA with 
XbaI (Gibco Invitrogen Corp.), as previously reported (Quintanilla et al., 1986). For 
p53, oligonucleotides to amplify a cDNA fragment containing exons 3-9 were used. The 
928-bp product was isolated and directly sequenced in an ABI PRISM 377 machine (PE 
Applied Biosystems, Foster city, CA, USA). See Supplementary Information for 
specific primers and PCR conditions. 
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Western blot analysis 
 Specific proteins were detected by using enhanced chemiluminiscence 
(Amersham Corporation, Arlington Heights, FL) and the following primary antibodies: 
rabbit polyclonal anti-p16 (1:250) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA), rabbit polyclonal anti-p19 (1:500) (raised against amino acids 54-75; kindly 
provided by Dr. I. Palmero, Instituto de Investigaciones Biomédicas, CSIC-UAM, 
Madrid, Spain) and mouse monoclonal anti--tubulin DM1A (1:10000) (Sigma 
Aldrich). As secondary antibodies, anti-mouse or anti-rabbit IgGs coupled to 
horseradish peroxidase (Nordic Immunological laboratories, Tilburg, The Netherlands) 
were used. 
 
Cytogenetic studies, spectral karyotyping and fluorescence in situ hybridization 
analysis 
 For conventional cytogenetic analysis, cells were exposed to colchicine (0.5 
g/ml) for 6 h at 37ºC, and harvested routinely. Metaphases were analyzed after 
standard Giemsa staining, C-banded and DAPI staining, as described (Bella et al., 
1995). 
 For SKY analysis, slide preparation and hybridization, using commercial probes, 
were carried out according to the manufacturer's instructions (Applied Spectral Imaging 
[ASI], Migdal Ha'Emek, Israel). Images were acquired using an ASI SD300 
Spectracube mounted on a Zeiss Axioplan 2 microscope. 
  For FISH studies, Ensembl Cytoview was used to select BAC clones covering 
regions C, D1, D3 and E3 from chromosome 15, and region A3 from chromosome 14. 
Clones were purchased from the Children Hospital Oakland Research Institute (CHORI; 
www.chori.org/bacpac/) and used for FISH analysis. All BACs were labelled directly 
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by nick translation with SpectrumGreen- or SpectrumOrange-dUTPs, according to the 
manufacturer’s specifications (Vysis, Dowers Grove, IL, USA). The probes were 
blocked with mouse Cot-1 DNA (Gibco Invitrogen Corp.) to suppress repetitive 
sequences. Metaphase spreads from the cell lines were hybridized overnight at 37ºC 
with labelled probes. After post-hybridization washes, the chromosomes were 
counterstained with DAPI in antifade solution. Cell images were captured using a CCD 
camera (Photometrics SenSys camera) connected to a computer running the 




 For tumorigenicity assays, 3x106 viable cells were i.d. injected into the two 
flanks of 8-week-old female athymic BALB/c nude mice (Harlan S. L., Barcelona, 
Spain). The latency period was estimated as the time needed for tumors to reach a size 
of 1-cm2. Histological typing of developed tumors was performed in formalin-fixed and 
paraffin-embedded sections by staining with hematoxylin and eosin. 
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Legends to figures 
 
Figure 1. Phase-contrast micrographs of the different cell lines. Bars, 100 m. 
 
Figure 2. Histological appearance of tumors induced by CarC (a and c) and CarC-R (b 
and d) in nude mice. Panels c and d show higher magnifications of sarcomatoid and 
epithelial differentiation areas, respectively. Note that tumors induced by both cell lines 
are highly undifferentiated, but the CarC-R tumor of panel b contains a small region of 
epithelial cell differentiation (marked with a dotted line) showed in panel d at a higher 
magnification.  
 
Figure 3. Characterization of H-Ras and INK4a gene expression. (a) Expression of 
normal and mutated H-Ras genes. A 400-bp mRNA product containing the codon 61 of 
murine H-Ras was amplified by RT-PCR using specific primers. The products were run 
on agarose-ethidium bromide gels before (upper panel) and after (middle panel) 
digestion with XbaI. Mutation of the middle base of codon 61 from A to T gives rise to 
a XbaI restriction site, generating fragments of 262-bp and 138-bp; n, normal H-Ras 
undigested with the enzyme; m, mutated H-Ras. Amplification of GAPDH mRNA was 
used as a control (bottom panel). Note in the middle panel that the relative band 
intensities of mutated versus normal fragments are increased in the fibroblastic (F3, F4, 
F5, F2) with respect to the epithelial (E2, E1, E4) cell clones. (b, c) Expression of 
p16INK4a and p19ARF genes by RT-PCR (b) and Western blotting (c). 
Immunodetection of -tubulin was used as a control for protein loading. (d) Induction 
of p16 expression by the demethylating agent 5-aza-dC. Representative Western blot of 
p16 protein expression after a 48 h treatment of CarC and CarC-R cells with 10 M 5-
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aza-dC or solvent (- 5-aza-dC). The PDV carcinoma cell line which contains a 2:1 ratio 
of normal to mutated H-Ras alleles (Quintanilla et al., 1991) and expresses p16 and p19 
genes was used as a positive control for all these experiments. 
 
Figure 4. Distribution of chromosome numbers of CarC and CarC-R cell lines. A total 
of 52 and 51 metaphases were analyzed in CarC and CarC-R, respectively. 
 
Figure 5. Spectral karyotypes from CarC and CarC-R cell lines. (a) SKY karyotype 
from a representative diploid CarC cell. Each chromosome pair is represented by a 
DAPI banded image (white box on the left) and the classified spectrum image (to the 
right of the banded image). (b) Detail of the reciprocal translocation between 
chromosome 14 and 15, which appears as two-coloured chromosomes. (c) SKY 
karyotype from a representative near-triploid CarC-R cell. Each chromosome is also 
represented by two images as in panel a. Several chromosome aberrations, such as 
dicentric chromosome 3;18, translocations involving chromosomes 4, 10, and 13, and 
amplifications involving chromosomes 11 and 12, are indicated. 
 
Figure 6. FISH analysis of the t(14;15) translocation. (a) Labelling scheme for 
detecting translocated chromosomes: a normal chromosme 15 appears with four 
hybridisation signals with the sequence green-red-green-red from centromere to 
telomere. The appearance of only two green-red signals indicates the presence of a 
translocated chromosome 14 or 15. (b) Metaphase spread from a CarC-R cell showing 
five normal chromosomes 15 and two translocated chromosomes (encircled in white). 
(c) Labelling scheme for detecting translocated chromosomes: a normal chromosome 15 
appears with two hybridisation signals with the sequence green-red from centromere to 
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telomere, while a normal chromosome 14 appears with a diffuse large green signal close 
to the centromere. Translocated chromosome 15 appears with a single green signal and 
translocated chromosome 14 appears with the diffuse large green signal and the 
additional more telomeric red signal from chromosome 15. (d) Metaphase spread from a 
CarC-R cell showing normal chromosomes 14 and 15 and translocated products 
(encircled in white). The finding of a der(15)T(14;15) and a der(14)T(14;15) within the 
same cell strongly suggests the presence of a reciprocal translocation involving 
chromosomes 14 and 15. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
